Related Articles

• An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries
• Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use
• Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA

Article Page

Pancreatic cancer is an incredibly challenging disease due to its high rates of resistance to traditional chemotherapy and radiotherapy. There has been little improvement in the prognosis of pancreatic cancer cases in the past decades, highlighting the crucial need for more effective therapeutic approaches. Erlotinib, an EGFR inhibitor, and gemcitabine, a nucleoside analog, are currently used in combination for chemotherapy treatment, but new developments in drug delivery systems using liposomes and nanoparticles may be promising new modalities for management of the disease. In addition to standard chemotherapeutic drugs, these delivery systems can be utilized to deliver therapeutic agents such as siRNA, oncolytic viruses, small molecule inhibitors, antibodies, and suicide genes. Further work is required to elucidate how ligands and antibodies could be used to enhance the targeted delivery of drugs, thus increasing specificity, improving stability, and reducing the effect of the drugs on healthy tissue. Despite significant preclinical data, there are currently very few clinical trials involving pancreatic cancer targeted drug delivery. This article summarizes current developments in targeted pancreatic cancer drug delivery, focusing on delivery systems, targets, and therapeutic agents.

Keywords: pancreatic cancer, EGFR, monoclonal antibodies, erlotinib, gemcitabine, FOLFIRINOX, siRNA, shRNA, p53, Rb, p21, p16, KRAS, liposomes, nanoparticles, suicide genes, oncolytic viruses, VEGFR, MUC1, mesothelin, carbon nanotubes

Citation: Zhang Y, Satoh K and Li M. Novel therapeutic modalities and drug delivery in pancreatic cancer – an ongoing search for improved efficacy Drugs in Context 2012;212244. doi: 10.7573/dic.212244

Provenance: Invited; externally peer reviewed

Dates: Submitted: 20 September 2012; Accepted subject to peer review: 27 September 2012; Published: 11 December 2012

Copyright: © 2012 Zhang Y, Satoh K and Li M. This is an open-access article distributed under the terms of the Creative Commons Attribution License Deed CC BY NC ND 3.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No other uses without permission.

Correct attribution: Copyright © 2012 Zhang Y, Satoh K and Li M. http://dx.doi.org/10.7573/dic.212244. Published by Drugs in Context under Creative Commons Attribution License Deed CC BY NC ND 3.0.

Correspondence: Min Li, PhD, The Vivian L. Smith Department of Neurosurgery, Department of Integrative Biology & Pharmacology, The University of Texas Medical School at Houston, 6431 Fannin Street, MSE R266, Houston, TX 77030, United States

Email: Min.Li@uth.tmc.edu